{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:46:52Z","timestamp":1793324812187,"version":"4.5.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,19]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>We performed an international retrospective study on 283 patients with light chain (AL) amyloidosis to investigate the prognostic impact of cytogenetic abnormalities by fluorescence in situ hybridization, when treated with frontline daratumumab\u2013based therapy. The cytogenetic subgroups of interest were t(11;14), gain\/amp(1q) (hereafter,\u00a0+1q), hyperdiploidy, deletion(13q), del(17p), and myeloma high-risk (HR) translocations (t[4;14], t[14;16], or t[14;20]). The end points of interest were rate of hematologic complete response (heme-CR), very good partial response (VGPR) or better, and hematologic event-free survival (heme-EFS). The incidence of abnormalities was as follows: t(11;14), 53.4%; deletion (13q), 28.9%;\u00a0+1q, 22.3%; hyperdiploidy, 19.4%; HR translocations, 6.6%; and deletion(17p), 4.5%. The heme-CR rate by cytogenetic subgroups were as follows: t(11;14) vs no t(11;14), 45.2% vs 41.8% (P=0.597); del(13q) vs no del(13q), 46.8% vs 42.8% (P=0.594);\u00a0+1q vs no\u00a0+1q, 30.2% vs 47.9% (P=0.022); hyperdiploidy vs no hyperdiploidy, 39.5% vs 44.9% (P=0.541); HR translocations vs none, 45.5% vs 43.1% (P=0.877); and del(17p) vs no del(17p), 50.0% vs 42.9% (P=0.658), respectively. Similarly,\u00a0+1q was the only subgroup with a\u00a0significantly lower VGPR or better rate (64.2% vs 79.0%; P=0.033). At a median follow-up of 19.8 months, the median heme-EFS was 49.6 months (95% CI, 24.7-not reached [NR]), and the 2-year overall survival (OS) was 80.98% (95% CI, 75.6-85.4). The presence of\u00a0+1q was significantly associated with worse heme-EFS on multivariate analysis (HR 2.06, 95% CI, 1.14-3.71; P=0.017). Notably, there was no adverse prognostic impact of t(11;14) on heme-EFS or OS. In conclusion,\u00a0+1q is\u00a0associated with worse outcome in the daratumumab-era. Clinical trials testing novel frontline immunotherapies should be enriched in\u00a0+1q to further improve outcomes in this subgroup.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024025899","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T15:16:50Z","timestamp":1724858210000},"page":"2613-2624","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Mayo Clinic Rochester, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-6746","authenticated-orcid":false,"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divaya","family":"Bhutani","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Mayo Clinic Rochester, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Mayo Clinic Rochester, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Mayo Clinic Rochester, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anannya","family":"Patwari","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cowan","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Oncology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5483-7178","authenticated-orcid":false,"given":"GuiZhen","family":"Chen","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Oncology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Milani","sequence":"additional","affiliation":[{"name":"6Department of Molecular Medicine, University of Pavia, Pavia, Italy"},{"name":"7Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-5138","authenticated-orcid":false,"given":"Giovanni","family":"Palladini","sequence":"additional","affiliation":[{"name":"6Department of Molecular Medicine, University of Pavia, Pavia, Italy"},{"name":"7Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-2445","authenticated-orcid":false,"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Boston University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1568-9460","authenticated-orcid":false,"given":"Geethika","family":"Bodanapu","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Boston University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Sch\u00f6nland","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Mayo Clinic Rochester, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2024121916205731700_bib1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for\u00a0immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024121916205731700_bib2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ajh.27179","article-title":"Reduced early mortality with daratumumab-based frontline therapy in AL amyloidosis: a retrospective cohort study","volume":"99","author":"Chakraborty","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"2024121916205731700_bib3","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/13506129.2022.2164488","article-title":"Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study","volume":"30","author":"Kumar","year":"2023","journal-title":"Amyloid"},{"issue":"6","key":"2024121916205731700_bib4","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/s41375-024-02243-5","article-title":"Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures","volume":"38","author":"Zanwar","year":"2024","journal-title":"Leukemia"},{"issue":"47","key":"2024121916205731700_bib5","doi-asserted-by":"crossref","first-page":"81735","DOI":"10.18632\/oncotarget.21052","article-title":"Importance of FISH genetics in light chain amyloidosis","volume":"8","author":"Gertz","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"2024121916205731700_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-020-00348-5","article-title":"Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response","volume":"10","author":"Abdallah","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"2024121916205731700_bib7","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J"},{"issue":"12","key":"2024121916205731700_bib8","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024121916205731700_bib9","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"issue":"18","key":"2024121916205731700_bib10","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019003633","article-title":"Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria","volume":"135","author":"Kimmich","year":"2020","journal-title":"Blood"},{"issue":"17","key":"2024121916205731700_bib11","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A\u00a0European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2024121916205731700_bib12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2024121916205731700_bib13","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A\u00a0staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"36","key":"2024121916205731700_bib14","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024121916205731700_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","article-title":"Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis","volume":"28","author":"Palladini","year":"2021","journal-title":"Amyloid"},{"issue":"3","key":"2024121916205731700_bib16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/leu.2017.286","article-title":"Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains","volume":"32","author":"Sidana","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"2024121916205731700_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","volume":"130","author":"Milani","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2024121916205731700_bib18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2024121916205731700_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"7","key":"2024121916205731700_bib20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2018-10-875252","article-title":"Staging systems use for risk stratification of\u00a0systemic amyloidosis in the era of high-sensitivity troponin T assay","volume":"133","author":"Muchtar","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2024121916205731700_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A\u00a0note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"1","key":"2024121916205731700_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.26399","article-title":"Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab","volume":"97","author":"Szalat","year":"2022","journal-title":"Am J Hematol"},{"issue":"14","key":"2024121916205731700_bib23","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2010-02-268987","article-title":"Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance\u00a0and inversely associated with translocation t(11;14)","volume":"117","author":"Bochtler","year":"2011","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/25\/2613\/2347052\/blood_bld-2024-025899-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/25\/2613\/2347052\/blood_bld-2024-025899-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T11:31:51Z","timestamp":1734607911000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/25\/2613\/517606\/Prognostic-impact-of-cytogenetic-abnormalities"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":23,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2024,12,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025899","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]}}}